Science
Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002 – The Korea Herald
SHANGHAI, Sept. 14, 2021 /PRNewswire/ — Recently, Jemincare group has declared that it has completed phase I clinical trial…
SHANGHAI, Sept. 14, 2021 /PRNewswire/ — Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002).
The clinical trial of JMB2002 was stated…
Continue Reading